411OInitial results from a phase I/IIa trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer. (23rd October 2018) - Hilton, J; Cristea, M C; Voskoboynik, M; Postel-Vinay, S; Edenfield, W; Gavai, A; Wee, S; Srivastava, N; Klippel, A; Jackson, D; Apfel, A; Chasalow, S D; et al.